Standout Papers

Pembrolizumab monotherapy for previously untreated, PD-L1-positive, metastatic triple-negative breast ca... 2018 2026 2020 2023 441
  1. Pembrolizumab monotherapy for previously untreated, PD-L1-positive, metastatic triple-negative breast cancer: cohort B of the phase II KEYNOTE-086 study (2018)
    Sylvia Adams, Sherene Loi et al. Annals of Oncology

Immediate Impact

1 by Nobel laureates 2 from Science/Nature 70 standout
Sub-graph 1 of 20

Citing Papers

Polymeric Nanoparticles for Drug Delivery
2024 Standout
Towards targeting the breast cancer immune microenvironment
2024 Standout
18 intermediate papers

Works of Yu Ding being referenced

LBA21 KEYNOTE-756: Phase III study of neoadjuvant pembrolizumab (pembro) or placebo (pbo) + chemotherapy (chemo), followed by adjuvant pembro or pbo + endocrine therapy (ET) for early-stage high-risk ER+/HER2– breast cancer
2023
Pembrolizumab monotherapy for previously untreated, PD-L1-positive, metastatic triple-negative breast cancer: cohort B of the phase II KEYNOTE-086 study
2018 Standout
and 3 more

Author Peers

Author Last Decade Papers Cites
Yu Ding 636 250 73 267 30 1.1k
Shanzhi Gu 421 165 129 176 55 1.1k
Federica Liotti 368 138 61 488 41 1.2k
Longsheng Hong 300 135 130 142 21 955
Seunghee Kang 427 133 100 207 26 1.1k
Lei Li 255 274 76 214 47 1.2k
Jamal Hill 512 135 32 162 32 1.1k
Mingfang Ao 490 163 82 184 26 1.2k
Mei Liang 314 138 63 271 38 1.0k
Pei‐Li Yao 374 93 75 420 32 1.4k
Huan Xu 317 234 80 180 56 1.2k

All Works

Loading papers...

Rankless by CCL
2026